Skip to main content
padlock icon - secure page this page is secure

Two‐stage design for phase I–II cancer clinical trials using continuous dose combinations of cytotoxic agents

Buy Article:

$47.00 + tax (Refund Policy)

  We present a two‐stage phase I–II design of a combination of two drugs in cancer clinical trials. The goal is to estimate safe dose combination regions with a desired level of efficacy. In stage I, conditional escalation with overdose control is used to allocate dose combinations to successive cohorts of patients and the maximum tolerated dose curve is estimated as a function of Bayes estimates of the model parameters. In stage II, we propose a Bayesian adaptive design for conducting the phase II trial to determine dose combination regions along the maximum tolerated dose curve with a desired level of efficacy. The methodology is evaluated by extensive simulations and application to a real trial.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Bayesian adaptive design; Cancer phase I–II trials; Cubic splines; Drug combination; Escalation with overdose control; Maximum tolerated dose

Document Type: Research Article

Publication date: 01 January 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more